ELVANSE

This brand name is authorized in Austria, Estonia, Finland, Netherlands, Poland, Spain, UK.

Active ingredients

The drug ELVANSE contains one active pharmaceutical ingredient (API):

1	Lisdexamfetamine UNII SJT761GEGS - LISDEXAMFETAMINE DIMESYLATE
	Lisdexamfetamine is rapidly absorbed from the gastrointestinal tract and hydrolysed primarily by red blood cells to dexamfetamine, which is responsible for the drug’s activity. Amfetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity.
	Read more about Lisdexamfetamine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ELVANSE Capsule, hard	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06BA12		N Nervous system → N06 Psychoanaleptics → N06B Psychostimulants, agents used for ADHD and nootropics → N06BA Centrally acting sympathomimetics
Discover more medicines within N06BA12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1781849, 1781850, 1781861, 1888083
ES	Centro de información online de medicamentos de la AEMPS	77642, 77643, 77644
FI	Lääkealan turvallisuus- ja kehittämiskeskus	078674, 174903, 370333, 424477, 494648, 510577, 539824
GB	Medicines & Healthcare Products Regulatory Agency	219638, 219641, 222633, 297621, 297626, 297630, 322712, 322721, 322726, 398590, 398593, 399395
NL	Z-Index G-Standaard, PRK	198382, 198390, 198404, 198412
PL	Rejestru Produktów Leczniczych	100343381, 100343398, 100343406